BioMarin's Palynziq (pegvaliase-pqpz) Receives FDA Approval for Phenylketonuria (PKU) in Adults
Shots:
- The approval is based on P-III PRISM-2 study results assessing Palynziq (pegvaliase-pqpz- 20mg qd or 40mg qd) in patients in ratio (2:1) with high level of phenylalanine (Phe)
- The P-III PRISM-2 study resulted in maintaining blood Phe level vs PBO in patients
- Palynziq (pegvaliase-pqpz- SC) is an enzyme substitution therapy of phenylalanine hydroxylase (PAH) enzyme helping in breaking down of Phe
Ref: Biomarin | Image: Biomarin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com